Evidence map›Paper›PMID 40733547›Full record

SynthesisViruses2025

Predictive Value of Hepatitis B Core-Related Antigen for Multiple Recurrence Outcomes After Treatment Cessation in Chronic Hepatitis B: A Meta-Analysis Study.

Guoyang Yu, Meiqi Cheng, Yuxin Duan, Minrong Kang, Ning Jiang, Wei Yan, Jianhua Yin

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Guoyang YuDepartment of Laboratory Medicine, Naval Medical Centre, Naval Medical University, Shanghai 200052, China.
Meiqi ChengDepartment of Laboratory Medicine, Naval Medical Centre, Naval Medical University, Shanghai 200052, China.ORCID 0009-0006-6198-2900
Yuxin DuanDepartment of Laboratory Medicine, Naval Medical Centre, Naval Medical University, Shanghai 200052, China.ORCID 0009-0001-3064-0231
Minrong KangDepartment of Laboratory Medicine, Naval Medical Centre, Naval Medical University, Shanghai 200052, China.
Ning JiangDepartment of Laboratory Medicine, Naval Medical Centre, Naval Medical University, Shanghai 200052, China.
Wei YanDepartment of Laboratory Medicine, Naval Medical Centre, Naval Medical University, Shanghai 200052, China.
Jianhua YinDepartment of Epidemiology, Naval Medical University, Shanghai 200433, China.ORCID 0000-0003-1047-7059

Funding

Program of Shanghai Academic Research Leader 22XD1404800 to JY
6 · The paper itself

Abstract

backgroundHepatitis B core-related antigen (HBcrAg), a novel serum biomarker reflecting the activity of intrahepatic covalently closed circular DNA (cccDNA), has generated conflicting evidence regarding its clinical utility for predicting post-antiviral therapy relapse in chronic hepatitis B (CHB) patients.

methodsWe systematically analyzed 13 studies (15 cohorts,

resultsHBcrAg demonstrated a pooled sensitivity of 0.81 (95% CI: 0.75-0.86) and specificity of 0.72 (95% CI: 0.67-0.76) for relapse prediction, with a diagnostic odds ratio of 10.66 (95% CI: 7.36-15.42) and summary AUC of 0.83 (95% CI: 0.80-0.86). Subgroup analysis identified threshold effects as the primary source of heterogeneity, which resolved (I

conclusionsHBcrAg is validated as a robust non-invasive biomarker to optimize treatment cessation strategies, with high sensitivity providing strong negative predictive value in CHB populations. Future research should prioritize multi-marker models to enhance prediction accuracy.

Indexed as

Hepatitis B, ChronicHepatitis B Core AntigensAntiviral AgentsBiomarkersHepatitis B virusHumansPredictive Value of TestsRecurrenceSensitivity and SpecificityTreatment OutcomeAntiviral AgentsBiomarkersHepatitis B Core AntigensCHB patientsHBcrAgmeta-analysistreatment cessation strategyviral relapse prediction

Identifiers

PMID40733547
PMCPMC12299212

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.